Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-Line Treatment
Clinical Lung Cancer（2022）
摘要
2019-004757-88 (EudraCT).
更多查看译文
关键词
EGFR,EGFRm Clearance,Liquid biopsy,Response-stratified therapy,Treatment escalation
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要